Status:
NOT_YET_RECRUITING
Spesolimab Post-marketing Surveillance in Korean Patients With Flares With Generalized Pustular Psoriasis
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Generalized Pustular Psoriasis
Eligibility:
All Genders
19+ years
Brief Summary
The primary and secondary objectives are to respectively monitor the safety and effectiveness of Spesolimab IV in Korean patients with flares with generalized pustular psoriasis (GPP) in a routine med...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients starting Spesolimab IV for the first time in accordance with the approved label in Korea (complete enumeration for the first 2 years after product launch)
- Patients with generalized pustular psoriasis (GPP) flare
- Age \>/=19 years at enrolment
- Patients who have signed the data release consent form
- Exclusion criteria:
- Patients with Severe or life-threatening hypersensitivity to Spesolimab or to any of the excipients
- Patients with clinically important active infections (e.g. active tuberculosis)
Exclusion
Key Trial Info
Start Date :
February 27 2026
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 8 2029
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT06886009
Start Date
February 27 2026
End Date
June 8 2029
Last Update
December 11 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Pusan National University Yangsan Hospital
Busan, South Korea, 49241
2
Ajou University Hospital
Gyeonggi-do, South Korea, 16499
3
Asan Medical Center
Seoul, South Korea, 05505
4
Samsung Medical Center
Seoul, South Korea, 06351